Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10271915" target="_blank" >RIV/00179906:_____/14:10271915 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/14:43875096 RIV/00216208:11160/14:10271915

Výsledek na webu

<a href="http://informahealthcare.com/doi/full/10.1517/14740338.2014.914168" target="_blank" >http://informahealthcare.com/doi/full/10.1517/14740338.2014.914168</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/14740338.2014.914168" target="_blank" >10.1517/14740338.2014.914168</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

Popis výsledku v původním jazyce

Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for an increasing number of people and countries. Populations suffering from AD financially strain the healthcare budgets of rich and poor countries alike. Moreover,no effective treatment is available and current drugs merely slow the progression of cognitive function deterioration and overall health status toward an inevitable end point. An increasing number of novel approaches have been tested in numerous clinicaltrials, but none of them has proved safe and effective for treating AD. Areas covered: This review summarizes all currently available compounds (donepezil, rivastigmine, galantamine, memantine) for the management of AD, concentrating on clinical aspectssuch as the mechanisms of action, pharmacokinetics, pharmacodynamics and clinical trials. This review also considers the mechanisms and side effects to provide perspective on current treatment options. Expert opinion: Novel approaches in

Název v anglickém jazyce

Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

Popis výsledku anglicky

Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for an increasing number of people and countries. Populations suffering from AD financially strain the healthcare budgets of rich and poor countries alike. Moreover,no effective treatment is available and current drugs merely slow the progression of cognitive function deterioration and overall health status toward an inevitable end point. An increasing number of novel approaches have been tested in numerous clinicaltrials, but none of them has proved safe and effective for treating AD. Areas covered: This review summarizes all currently available compounds (donepezil, rivastigmine, galantamine, memantine) for the management of AD, concentrating on clinical aspectssuch as the mechanisms of action, pharmacokinetics, pharmacodynamics and clinical trials. This review also considers the mechanisms and side effects to provide perspective on current treatment options. Expert opinion: Novel approaches in

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

O - Projekt operacniho programu

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion on Drug Safety

ISSN

1474-0338

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

16

Strana od-do

759-774

Kód UT WoS článku

000336531500010

EID výsledku v databázi Scopus

—